These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 28793154

  • 21. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN, Gooderham MJ.
    J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
    Vico-Alonso C, Sánchez-Velázquez A, Pinilla-Martin B, Andrés-Lencina JJ, Aragón-Miguel R, Calleja-Algarra A, Rivera-Díaz R.
    Int J Dermatol; 2020 Apr; 59(4):e102-e103. PubMed ID: 31347142
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Apremilast in psoriasis - a prospective real-world study.
    Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L.
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [Abstract] [Full Text] [Related]

  • 26. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A.
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC.
    J Drugs Dermatol; 2018 Feb 01; 17(2):221-228. PubMed ID: 29462231
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K.
    J Drugs Dermatol; 2017 Aug 01; 16(8):801-808. PubMed ID: 28809995
    [Abstract] [Full Text] [Related]

  • 29. Drug survival of apremilast in patients treated for psoriasis in a real-world setting.
    Lee EB, Amin M, Wu JJ.
    J Am Acad Dermatol; 2018 Oct 01; 79(4):760-761. PubMed ID: 29588246
    [No Abstract] [Full Text] [Related]

  • 30. Purpura annularis telangiectodes: Majocchi's disease. A case report.
    Wolf WB, Collis S.
    J Am Podiatry Assoc; 1977 Sep 01; 67(9):661-2. PubMed ID: 903571
    [No Abstract] [Full Text] [Related]

  • 31. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M, Papp K.
    Skin Therapy Lett; 2015 Sep 01; 20(5):1-6. PubMed ID: 26382906
    [Abstract] [Full Text] [Related]

  • 32. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 33. Successful treatment of psoriasis vulgaris with apremilast in a patient with decompensated cirrhosis.
    Yatsuzuka K, Murakami M, Yoshida S, Utsunomiya R, Watanabe T, Sayama K.
    J Dermatol; 2022 Apr 01; 49(4):e129-e130. PubMed ID: 34854129
    [No Abstract] [Full Text] [Related]

  • 34. Management of Common Side Effects of Apremilast.
    Langley A, Beecker J.
    J Cutan Med Surg; 2018 Apr 01; 22(4):415-421. PubMed ID: 29290125
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.
    J Eur Acad Dermatol Venereol; 2013 Mar 01; 27(3):e376-83. PubMed ID: 23030767
    [Abstract] [Full Text] [Related]

  • 36. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.
    Ighani A, Georgakopoulos JR, Shear NH, Walsh S, Yeung J.
    J Am Acad Dermatol; 2018 Nov 01; 79(5):953-956. PubMed ID: 29730366
    [No Abstract] [Full Text] [Related]

  • 37. Severe bitter taste associated with apremilast.
    Damiani G, Bragazzi NL, Grossi E, Petrou S, Radovanovic D, Rizzi M, Atzeni F, Sarzi-Puttini P, Santus P, Pigatto PD, Franchi C.
    Dermatol Ther; 2019 May 01; 32(3):e12876. PubMed ID: 30882959
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J.
    J Cutan Med Surg; 2018 May 01; 22(3):290-296. PubMed ID: 29373924
    [Abstract] [Full Text] [Related]

  • 39. Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
    Takama H, Shibata T, Ando Y, Yanagishita T, Ohshima Y, Akiyama M, Watanabe D.
    Eur J Dermatol; 2020 Apr 01; 30(2):188-190. PubMed ID: 32538362
    [No Abstract] [Full Text] [Related]

  • 40. Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.
    Rothstein BE, McQuade B, Greb JE, Goldminz AM, Gottlieb AB.
    J Drugs Dermatol; 2016 May 01; 15(5):648-9. PubMed ID: 27168275
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.